Overview

The Prevent Severe COVID-19 (PRESECO) Study

Status:
Recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection

Phase:

Phase 3

Details

Lead Sponsor:

Appili Therapeutics Inc.

Treatments:

Favipiravir